216 related articles for article (PubMed ID: 14719066)
21. Reduced acetylated histone H4 is associated with promoter methylation of the fragile histidine triad gene in resected esophageal squamous cell carcinoma.
Tzao C; Sun GH; Tung HJ; Hsu HS; Hsu WH; Wang YC; Cheng YL; Lee SC
Ann Thorac Surg; 2006 Aug; 82(2):396-401; discussion 401. PubMed ID: 16863736
[TBL] [Abstract][Full Text] [Related]
22. Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma.
Willenbrock K; Küppers R; Renné C; Brune V; Eckerle S; Weidmann E; Bräuninger A; Hansmann ML
Haematologica; 2006 May; 91(5):596-604. PubMed ID: 16670065
[TBL] [Abstract][Full Text] [Related]
23. Contig array CGH at 3p14.2 points to the FRA3B/FHIT common fragile region as the target gene in diffuse large B-cell lymphoma.
Kameoka Y; Tagawa H; Tsuzuki S; Karnan S; Ota A; Suguro M; Suzuki R; Yamaguchi M; Morishima Y; Nakamura S; Seto M
Oncogene; 2004 Dec; 23(56):9148-54. PubMed ID: 15480422
[TBL] [Abstract][Full Text] [Related]
24. Genetic polymorphisms of methylenetetrahydrofolate reductase and promoter methylation of MGMT and FHIT genes in diffuse large B cell lymphoma risk in Middle East.
Siraj AK; Ibrahim M; Al-Rasheed M; Bu R; Bavi P; Jehan Z; Abubaker J; Murad W; Al-Dayel F; Ezzat A; El-Solh H; Uddin S; Al-Kuraya K
Ann Hematol; 2007 Dec; 86(12):887-95. PubMed ID: 17712558
[TBL] [Abstract][Full Text] [Related]
25. Alterations of the fragile histidine triad gene in hepatitis C virus-associated hepatocellular carcinoma.
Zekri AR; Bahnassy AA; Hafez M; El-Shehaby AM; Sherif GM; Khaled HM; Zakhary N
J Gastroenterol Hepatol; 2005 Jan; 20(1):87-94. PubMed ID: 15610452
[TBL] [Abstract][Full Text] [Related]
26. Aberrant fragile histidine triad gene transcripts in primary hepatocellular carcinoma and liver cirrhosis.
Gramantieri L; Chieco P; Di Tomaso M; Masi L; Piscaglia F; Brillanti S; Gaiani S; Valgimigli M; Mazziotti A; Bolondi L
Clin Cancer Res; 1999 Nov; 5(11):3468-75. PubMed ID: 10589760
[TBL] [Abstract][Full Text] [Related]
27. [Allelic loss and down-regulation of FHIT gene expression in esophageal squamous cell carcinoma].
Liu FX; Huang XP; Zhao CX; Xu X; Han YL; Cai Y; Wu RL; Wu M; Zhan QM; Wang MR
Ai Zheng; 2004 Sep; 23(9):992-8. PubMed ID: 15363189
[TBL] [Abstract][Full Text] [Related]
28. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease.
Campiglio M; Pekarsky Y; Menard S; Tagliabue E; Pilotti S; Croce CM
Cancer Res; 1999 Aug; 59(16):3866-9. PubMed ID: 10463571
[TBL] [Abstract][Full Text] [Related]
29. Expression of the fragile histidine triad gene in normal rat tissues and human kidney cancer cell lines.
Lee SH; Kim TJ; Kim HY; Kim JG; Park MK; Woo KM; Kim SH; Hwang KY; Nam HS; Min YK; Cho MH
Res Commun Mol Pathol Pharmacol; 2002; 112(1-4):145-57. PubMed ID: 15080505
[TBL] [Abstract][Full Text] [Related]
30. Abnormal fragile histidine triad (FHIT) expression in advanced cervical carcinoma: a poor prognostic factor.
Krivak TC; McBroom JW; Seidman J; Venzon D; Crothers B; MacKoul PJ; Rose GS; Carlson JW; Birrer MJ
Cancer Res; 2001 Jun; 61(11):4382-5. PubMed ID: 11389064
[TBL] [Abstract][Full Text] [Related]
31. FHIT expression in clear cell renal carcinomas: versatility of protein levels and correlation with survival.
Ramp U; Caliskan E; Ebert T; Karagiannidis C; Willers R; Gabbert HE; Gerharz CD
J Pathol; 2002 Apr; 196(4):430-6. PubMed ID: 11920739
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas.
Goldberg M; Rummelt C; Laerm A; Helmbold P; Holbach LM; Ballhausen WG
Br J Dermatol; 2006 Dec; 155(6):1154-8. PubMed ID: 17107382
[TBL] [Abstract][Full Text] [Related]
33. Inverse correlation of aberrant expression of fragile histidine triad (FHIT) protein with cyclin D1 protein and prognosis in Chinese patients with cholangiocarcinoma.
Zhao P; Lu Y; Zhong M; Liu L; Li B
Acta Oncol; 2008; 47(8):1557-63. PubMed ID: 18618300
[TBL] [Abstract][Full Text] [Related]
34. Multiple molecular alterations of FHIT in betel-associated oral carcinoma.
Chang KW; Kao SY; Tzeng RJ; Liu CJ; Cheng AJ; Yang SC; Wong YK; Lin SC
J Pathol; 2002 Mar; 196(3):300-6. PubMed ID: 11857493
[TBL] [Abstract][Full Text] [Related]
35. 5'CpG island hypermethylation and aberrant transcript splicing both contribute to the inactivation of the FHIT gene in resected non-small cell lung cancer.
Tzao C; Tsai HY; Chen JT; Chen CY; Wang YC
Eur J Cancer; 2004 Sep; 40(14):2175-83. PubMed ID: 15341994
[TBL] [Abstract][Full Text] [Related]
36. Aberrant FHIT transcripts in human colorectal cancers.
Lee SH; Lee SH
Res Commun Mol Pathol Pharmacol; 2005; 117-118():153-65. PubMed ID: 18426086
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer.
Woenckhaus M; Merk J; Stoehr R; Schaeper F; Gaumann A; Wiebe K; Hartmann A; Hofstaedter F; Dietmaier W
Hum Pathol; 2008 Jan; 39(1):126-36. PubMed ID: 17949785
[TBL] [Abstract][Full Text] [Related]
38. Aberrant splicing of FHIT transcripts in human gastric cancer cell lines.
Lee SH; Kim HY; Kim TJ; Park HK; Kim WH; Woo KM; Cho MH
Res Commun Mol Pathol Pharmacol; 2002; 112(1-4):39-49. PubMed ID: 15080495
[TBL] [Abstract][Full Text] [Related]
39. MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression.
Uccella S; Cerutti R; Placidi C; Marchet S; Carnevali I; Bernasconi B; Proserpio I; Pinotti G; Tibiletti MG; Furlan D; Capella C
J Clin Pathol; 2009 Aug; 62(8):715-23. PubMed ID: 19638543
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of fragile histidine triad expression in tumors from saudi arabia: a tissue microarray analysis.
Bavi P; Jehan Z; Atizado V; Al-Dossari H; Al-Dayel F; Tulbah A; Amr SS; Sheikh SS; Ezzat A; El-Solh H; Uddin S; Al-Kuraya K
Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1708-18. PubMed ID: 16985034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
